stockrow
Friday 6 November 2026
Export WRBY’s income statement to Excel — free account
Warby Parker Inc.
WRBY Healthcare Medical Instruments & Supplies
Warby Parker Inc.’s revenue for fiscal 2025 (year ended December 2025) was $871.9 million, up 13.0% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −20.0%
- Free cash flow
- −30.3%
Quarter to September 2026, against a year earlier
26.05
4.76
+22.36%
Follow WRBY
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
463.00 | 433.43 | 1,342.04 | 1,387.90 |
+8 more quarters Free account |
P/S ratio |
3.71 | 4.12 | 2.92 | 3.07 | |
P/FCF ratio |
162.75 | 172.91 | 66.85 | 61.11 | |
P/Operating CF |
140.13 | 126.96 | 106.11 | 114.95 | |
P/B ratio |
8.59 | 9.59 | 6.92 | 7.27 | |
Price to Tangible BV |
8.59 | 9.59 | 6.92 | 7.27 | |
EV/Sales |
3.40 | 3.80 | 2.60 | 2.74 | |
EV/EBITDA |
53.84 | 58.77 | 46.78 | 49.36 | |
EV/Operating CF |
31.11 | 36.36 | 21.83 | 21.54 | |
EV/FCF |
149.22 | 159.46 | 59.44 | 54.57 | |
Quick Ratio |
1.79 | 1.80 | 1.89 | 1.93 | |
Current Ratio |
2.26 | 2.27 | 2.33 | 2.35 | |
Net Debt/EBITDA |
0.00 | (16.01) | (17.52) | (39.43) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.25 | 1.24 | 1.26 | 1.25 | |
Operating CF/Net income |
4.41 | 6.38 | 7.72 | (3.91) | |
Capex/Depreciation |
0.00 | (1.51) | (1.09) | (1.07) | |
Interest Coverage |
(1.36) | (1.52) | (0.72) | 3.89 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
52.96% | 56.60% | 53.36% | 55.62% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
3.49% | 4.21% | 4.70% | 2.96% | |
Graham Net Nets |
(0.01) | 0.00 | 0.00 | 0.00 | |
Graham Number |
2.09 | 2.23 | 1.04 | 1.03 | |
Earnings Yield |
0.22% | 0.23% | 0.07% | 0.07% | |
Free Cash Flow Yield |
0.61% | 0.58% | 1.50% | 1.64% | |
Revenue per Share |
1.96 | 1.90 | 1.96 | 1.73 | |
Operating CF per Share |
0.20 | 0.24 | 0.20 | 0.19 | |
Capex per Share |
(0.21) | (0.18) | (0.13) | (0.12) | |
Free Cash Flow per Share |
(0.02) | 0.05 | 0.07 | 0.07 | |
Cash per Share |
2.31 | 2.36 | 2.34 | 2.33 | |
Shareholders Equity per Share |
3.23 | 3.16 | 3.04 | 3.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.23 | 3.16 | 3.04 | 3.00 | |
Free Cash Flow |
(1.97) | 6.76 | 8.37 | 8.13 | |
Working Capital |
203.91 | 207.36 | 204.41 | 202.31 | |
Capital Expenditures |
(26.70) | (22.86) | (16.14) | (15.12) | |
Net Current Asset Value |
(22.67) | (9.49) | (2.91) | (0.75) | |
EV/EBIT |
2,063.83 | 2,234.08 | 0.00 | 0.00 | |
Capex to Sales |
0.11 | 0.10 | 0.07 | 0.07 | |
Price to Operating Income |
2,250.90 | 2,422.65 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.64 | 1.61 | 1.62 | 2.62 | |
Average Payables |
19.81 | 33.65 | 31.88 | 27.75 | |
Average Inventory |
45.94 | 42.69 | 47.53 | 48.43 | |
Average Assets |
749.54 | 737.11 | 709.58 | 698.70 | |
Average Common Equity |
386.49 | 376.72 | 364.95 | 353.90 |
Columns are period end dates · fundamentals updated 5 Nov 2026